Compare Stocks

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NRIFF Nuvo Pharmaceuticals		$0.75	$0.30 ▼ $0.87	$8.52M	1.57	7,337 shs	3,000 shs
PXYN Praxsyn		$0.00	$0.00 ▼ $0.01	$85K	-1.01	N/A	N/A
SNNA Sienna Biopharmaceuticals	$0.14	$0.14	$0.06 ▼ $3.80	$4.20M	2.67	1.87 million shs	13.32 million shs
XBIO Xenetic Biosciences	$4.00 +3.6%	$4.07	$2.55 ▼ $5.97	$6.16M	2.6	6,022 shs	7,896 shs

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NRIFF Nuvo Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
PXYN Praxsyn	0.00%	0.00%	0.00%	0.00%	0.00%
SNNA Sienna Biopharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
XBIO Xenetic Biosciences	-3.86%	-17.63%	-9.18%	+12.87%	-16.99%

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
NRIFF Nuvo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PXYN Praxsyn	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SNNA Sienna Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XBIO Xenetic Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NRIFF Nuvo Pharmaceuticals	N/A	N/A	N/A	N/A
PXYN Praxsyn	N/A	N/A	N/A	N/A
SNNA Sienna Biopharmaceuticals	N/A	N/A	N/A	N/A
XBIO Xenetic Biosciences	2.00	Hold	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NRIFF Nuvo Pharmaceuticals	$52.41M	0.00	N/A	0.82	$1.59 per share	0.00
PXYN Praxsyn	N/A	N/A	N/A	N/A	N/A	N/A
SNNA Sienna Biopharmaceuticals	N/A	N/A	N/A	N/A	$1.27 per share	N/A
XBIO Xenetic Biosciences	$2.54M	2.43	N/A	N/A	$6.36 per share	0.63

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NRIFF Nuvo Pharmaceuticals	$2.53M	$0.04	18.69	N/A	N/A	-2.81%	8.02%	1.11%	N/A
PXYN Praxsyn	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
SNNA Sienna Biopharmaceuticals	-$73.47M	-$3.59	N/A	N/A	N/A	N/A	-177.36%	-52.22%	N/A
XBIO Xenetic Biosciences	-$4.14M	-$2.75	N/A	N/A	N/A	-162.84%	-36.43%	-33.74%	5/9/2024 (Estimated)

Latest NRIFF, PXYN, SNNA, and XBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/21/2024	Q4 2023	XBIO Xenetic Biosciences	-$0.87	-$0.77	+$0.10	-$0.77	$0.68 million	$0.67 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
NRIFF Nuvo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PXYN Praxsyn	N/A	N/A	N/A	N/A	N/A
SNNA Sienna Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
XBIO Xenetic Biosciences	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NRIFF Nuvo Pharmaceuticals	5.27	2.67	2.11
PXYN Praxsyn	N/A	N/A	N/A
SNNA Sienna Biopharmaceuticals	N/A	15.27	15.27
XBIO Xenetic Biosciences	N/A	11.84	11.84

Ownership

Institutional Ownership

Company	Institutional Ownership
NRIFF Nuvo Pharmaceuticals	N/A
PXYN Praxsyn	N/A
SNNA Sienna Biopharmaceuticals	17.36%
XBIO Xenetic Biosciences	15.12%

Insider Ownership

Company	Insider Ownership
NRIFF Nuvo Pharmaceuticals	N/A
PXYN Praxsyn	N/A
SNNA Sienna Biopharmaceuticals	27.20%
XBIO Xenetic Biosciences	9.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
NRIFF Nuvo Pharmaceuticals	99	11.40 million	N/A	Not Optionable
PXYN Praxsyn	66	847.94 million	N/A	Not Optionable
SNNA Sienna Biopharmaceuticals	39	30.91 million	N/A	Not Optionable
XBIO Xenetic Biosciences	4	1.54 million	1.40 million	Not Optionable

NRIFF, PXYN, SNNA, and XBIO Headlines

Source	Headline
	Xenetic Biosciences Inc (NASDAQ:XBIO) Sees Large Drop in Short Interest americanbankingnews.com - April 13 at 3:22 AM
	Xenetic Biosciences Inc (XBIO) investing.com - April 10 at 3:28 PM
	Xenetic Biosciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag finance.yahoo.com - March 24 at 5:09 PM
	Xenetic Dips on Full-Year Results baystreet.ca - March 22 at 7:33 PM
	Xenetic Biosciences reports FY results msn.com - March 22 at 8:51 AM
	Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results accesswire.com - March 22 at 8:00 AM
	Xenetic to advance DNase programme with UVA partnership msn.com - January 18 at 1:37 PM
	Xenetic Biosciences Inc XBIO morningstar.com - January 4 at 5:10 PM
	Xenetic Biosciences Stock (NASDAQ:XBIO), Guidance and Forecast benzinga.com - December 11 at 9:01 AM
	Most Shareholders Will Probably Agree With Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation finance.yahoo.com - November 30 at 10:39 AM
	Xenetic Biosciences: Q3 Earnings Insights benzinga.com - November 10 at 3:38 PM
	MediciNova: Q3 Earnings Snapshot washingtonpost.com - November 10 at 10:37 AM
	Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference finance.yahoo.com - October 11 at 9:30 AM
	Xenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock? msn.com - July 13 at 1:44 PM
	Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update finance.yahoo.com - May 11 at 5:06 PM
	Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison \| Morningstar morningstar.com - May 5 at 10:21 AM
	Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development finance.yahoo.com - May 4 at 10:02 AM
	Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison finance.yahoo.com - May 3 at 10:26 AM
	HC Wainwright & Co. Reiterates Xenetic Biosciences (XBIO) Buy Recommendation msn.com - April 12 at 10:37 PM
	Xenetic Biosciences forms research collaboration with TSRI pharmaceutical-technology.com - April 12 at 12:36 PM
	Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Xenetic Biosciences (XBIO) markets.businessinsider.com - April 12 at 2:30 AM
	Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform finance.yahoo.com - April 11 at 8:43 AM
	JTC Team, LLC: JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences finanznachrichten.de - March 16 at 12:09 PM
	JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences finance.yahoo.com - March 16 at 12:09 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Nuvo Pharmaceuticals

OTCMKTS:NRIFF

Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. Nuvo Pharmaceuticals was founded on August 22, 1983 and is headquartered in Mississauga, Canada.

Praxsyn

OTCMKTS:PXYN

Praxsyn Corporation, a health care company, provides medical practitioners with medications and services for their patients. It formulates non-narcotic and non-habit forming medications using therapeutic and preventative agents in the forms of transdermal creams, patches, and oral capsules for pain management, erectile dysfunction, and metabolic therapies. Praxsyn Corporation provides its products to patients covered under the California workers' compensation system, as well as preferred provider contracts. The company was formerly known as The PAWS Pet Company, Inc. and changed its name to Praxsyn Corporation in March 2014. Praxsyn Corporation was founded in 2005 and is headquartered in Las Vegas, Nevada.

Sienna Biopharmaceuticals

NASDAQ:SNNA

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery, clinical development, and commercialization of aesthetics and medical dermatology. Its products include Topical by Design platform for patients with inflammatory skin diseases and other dermatologic and aesthetic conditions through SNA-120, SNA-125, and SNA-001. The company was founded by Todd Harris and Frederick C. Beddingfield III on July 27, 2010 and is headquartered in Westlake Village, CA.

Xenetic Biosciences

NASDAQ:XBIO

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial